- Building on Success in Paraguay to Establish a Strategic Foothold in South America
- Strengthening Global Commercialization of its AI-Driven Organ Regeneration Platform

ROKIT Healthcare (KOSDAQ 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, has officially entered Argentina, the second-largest medical market in South America, aiming to dominate the regional cartilage regeneration market.

ROKIT Healthcare announced it has signed an AI-driven cartilage regeneration platform contract with Laboratorio Varifarma, a prominent medical network in Argentina. This agreement goes beyond a simple product supply deal; it is a strategic expansion leveraging the company's successful track record and clinical references in neighboring Paraguay.

■ Establishing a ‘South American Regenerative Medicine Belt’

The entry into Argentina is a direct result of ROKIT Healthcare’s "reference-based expansion" strategy. The proven clinical cases, trust from medical professionals, and positive patient outcome data from Paraguay played a decisive role in lowering the entry barriers to the Argentine market.

Unlike traditional artificial joint replacement surgeries, ROKIT’s technology is being recognized for shifting the local treatment paradigm. It minimizes surgical burden, shortens recovery time, and offers long-term tissue regeneration possibilities through its unique technological differentiation.

■ Targeting the High-Growth Market and Securing Recurring Revenue

Argentina is the second-largest healthcare market in South America, growing rapidly at over 15% annually. It serves as a key hub for cartilage and joint treatments, with an estimated arthritis patient population of over 5 million. Through this expansion, ROKIT Healthcare has not only gained immediate access to local hospital networks but has also established a sustainable platform revenue model capable of generating continuous profit.

Industry experts evaluate this achievement as a reconfirmation of the global scalability of ROKIT Healthcare’s AI-driven cartilage regeneration platform. It is expected to provide strong momentum for ongoing clinical trials in South Korea and regulatory approvals/market entry initiatives in the United States.

“The contract in Argentina is a strategic link that connects our clinical capabilities in Korea, our push into the U.S. regulatory system, and our rapid commercialization success in South America,” said an official from ROKIT Healthcare. “We will prove globally that our platform is the ‘standard for regenerative medicine’ and accelerate the era of regeneration, where damaged tissues are restored to their original state.”